VX-950 (Vertex/Mitsubishi).
Vertex and Mitsubishi are developing VX-950 (LY-570310), the lead compound from a program of small-molecule inhibitors of the hepatitis C virus (HCV) NS3 protease, for the potential treatment of HCV infection. In November 2004, Vertex initiated a phase Ib European trial of VX-950 for the treatment of HCV infection.
Summa
Vincenzo
V
Merck & Co, Department of Medicinal Chemistry, IRBM-MRL Rome, Pomezia, Rome, Italy. Vincenzo_summa@merck.com
D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D009842:Oligopeptides / Q000009:adverse effects* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D010330:Patents as Topic; D011480:Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors*; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases
D000998:Antiviral Agents; D009842:Oligopeptides; D011480:Protease Inhibitors; D017361:Viral Nonstructural Proteins; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; C486464:telaprevir